Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
Takenaka T, Itoh K, Suzuki T, Utsunomiya A, Matsuda S, Chou T, Sai T, Sano M, Konda S, Ohno T, Mikuni C, Deura K, Yamada T, Mizorogi F, Nagoshi H, Tomonaga M, Hotta T, Kawano K, Tsushita K, Hirano M, Shimoyama M; Lymphoma Study Group of the Japan Clinical Oncology Group. Takenaka T, et al. Among authors: shimoyama m. Int J Hematol. 2004 Feb;79(2):165-73. doi: 10.1532/ijh97.03115. Int J Hematol. 2004. PMID: 15005346 Clinical Trial.
A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Ishizuka N, Tomonaga M, Sai T, Ohno Y, Kasai M, Ogura M, Mikuni C, Toki H, Sano M, Masaki Y, Ohtsu T, Matsuno Y, Takenaka T, Shirakawa S, Shimoyama M; Japan Clinical Oncology Group. Kinoshita T, et al. Among authors: shimoyama m. Int J Hematol. 2004 Nov;80(4):341-50. doi: 10.1532/ijh97.04085. Int J Hematol. 2004. PMID: 15615259 Clinical Trial.
Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109).
Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, Tomonaga M, Araki K, Kasai M, Takatsuki K, Tara M, Mikuni C, Hotta T; Lymphoma Study Group of the Japan Clinical Oncology Group. Tsukasaki K, et al. Among authors: shimoyama m. Int J Hematol. 2003 Feb;77(2):164-70. doi: 10.1007/BF02983215. Int J Hematol. 2003. PMID: 12627852 Clinical Trial.
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.
Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, Ogura M, Hirano M, Asaoku H, Kurosawa M, Maeda Y, Omachi K, Moriuchi Y, Kasai M, Ohnishi K, Takayama N, Morishima Y, Tobinai K, Kaba H, Yamamoto S, Fukuda H, Kikuchi M, Yoshino T, Matsuno Y, Hotta T, Shimoyama M. Itoh K, et al. Among authors: shimoyama m. Int J Hematol. 2010 Apr;91(3):446-55. doi: 10.1007/s12185-010-0533-9. Epub 2010 Mar 3. Int J Hematol. 2010. PMID: 20198461
Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508.
Kagami Y, Itoh K, Tobinai K, Fukuda H, Mukai K, Chou T, Mikuni C, Kinoshita T, Fukushima N, Kiyama Y, Suzuki T, Sasaki T, Watanabe Y, Tsukasaki K, Hotta T, Shimoyama M, Ogura M; Lymphoma Study Group of the Japan Clinical Oncology Group. Kagami Y, et al. Among authors: shimoyama m. Int J Hematol. 2012 Jul;96(1):74-83. doi: 10.1007/s12185-012-1101-2. Epub 2012 Jun 3. Int J Hematol. 2012. PMID: 22661011 Clinical Trial.
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M. Ogura M, et al. Among authors: shimoyama m. Int J Hematol. 2010 Dec;92(5):713-24. doi: 10.1007/s12185-010-0712-8. Epub 2010 Nov 16. Int J Hematol. 2010. PMID: 21076995 Clinical Trial.
STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas.
Yoshida N, Tsuzuki S, Karube K, Takahara T, Suguro M, Miyoshi H, Nishikori M, Shimoyama M, Tsukasaki K, Ohshima K, Seto M. Yoshida N, et al. Among authors: shimoyama m. Cancer Sci. 2015 Oct;106(10):1455-62. doi: 10.1111/cas.12742. Epub 2015 Aug 13. Cancer Sci. 2015. PMID: 26176172 Free PMC article.
Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y; Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG). Ogura M, et al. Among authors: shimoyama m. Leuk Lymphoma. 2013 Jan;54(1):46-52. doi: 10.3109/10428194.2012.705000. Epub 2012 Aug 21. Leuk Lymphoma. 2013. PMID: 22712838 Clinical Trial.
645 results